Pharmafile Logo

Another year, another B!

Louise Jones, Cuttsy+Cuttsy’s Sustainability Officer reflects on their latest year of carbon reporting through CDP and on achieving another B rating.

Text reads 'We couldn't 'B' happier alongside CDP logo.

Yes, we’ve been awarded another B rating from Carbon Disclosure Project (CDP)! This is the second-highest rating available from CDP (which monitors environmental impact and risk management) and shows that we have been able to maintain our commitment to sustainability for the past 12 months, resulting in us being rewarded with another top rating!

The past year has been particularly momentous for us; we achieved net zero in both Scopes 1 and 2 (you’ll find more about the scope definitions here), which means we have just Scope 3 to conquer. Scope 3, which encompasses emissions resulting from the entire value chain, represents our last barrier to becoming a net zero company. And while achieving true net zero may be a challenge given the current technological landscape, our commitment is unwavering. We’re absolutely determined to get as close to zero as humanly possible!

Disclosing our progress through CDP is a crucial part of our bigger sustainability strategy, and with two years of experience under our belts, we’re embracing new changes in CDP’s submission structure as we head into 2024.

We’ve definitely encountered some roadblocks along the way. The main one being the complexity and time needed to accurately carbon report.

But there is light – after attending the CDP conference last year, we were given the welcome news of the questionnaire’s re-design, which hugely simplifies the reporting process. Firstly, by improving user-friendliness, and secondly (which is likely to be a very significant and far-reaching change), the merging of the climate, forestry, and water questionnaires. This promises to not only streamline the reporting process but for the likes of yours truly who is tasked with annual reporting, brings huge relief!

These changes are also likely to be big drivers in getting get more companies to participate in the scheme and disclose the details of their sustainability efforts. Because an accurate measurement of everyone’s impact is, after all, the only way to achieve true and effective global change. And CDP are clearly showing their commitment to this critical goal.

As we navigate through these improvements and challenges, Cuttsy+Cuttsy remains steadfast in its commitment to sustainability. And we look forward to making even greater strides in the coming years. Here’s to another year of progress and collective efforts towards a sustainable future.

This content was provided by Cuttsy + Cuttsy

Company Details

 Latest Content from  Cuttsy + Cuttsy 

Invited, but not equipped: patient involvement needs more than an open door

Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.

The outcomes are already chosen. So when can patients really shape them?

Explore why involving patients early in Joint Scientific Consultations is critical to shaping the outcomes measured in clinical trials.

Long-term clinical trial engagement is a behavioural challenge – not just an informational one

Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.

Patients are telling the truth — just not to you

Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.

When what matters to patients is hard to measure

Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

A seat at the table: what the EU HTA reforms really ask of patient involvement

The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.

Why faster trials make participant understanding more important than ever

As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.

Older trial participants reject bad design, not technology

Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.

5 key takeaways from the Patient Centricity and Engagement Conference

Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.